The particularly low diagnostic yield provides evidence that there is no need for staging brain MRI in cStage IA disease, including GGNs, whereas staging brain MRI should be considered in cStage IB disease (the yield was 3.8%) or epidermal growth factor receptor (EGFR) mutation-positive adenocarcinoma (17.5%) [14]. The gene discussed is EGFR; the disease is adenocarcinoma.